Come listen to MedSIR Founders Maria Campos, Dr. Javier Cortés, and Dr. Antonio Llombart speak about the MedSIR concept and how we are currently optimizing clinical research in Oncology.

Don’t miss Dr. José Perez, Breast Cancer Specialist, speaking about the role MedSIR plays in his everyday research.

WELCOME TO MEDSIR!

Here we are dedicated to the design and management of clinical trials involving some of the most important current drugs in Oncology such as osimertinib, pembrolizumab, pertuzumab, T-DM1, olaparib, niraparib, eribulin, palbociclib, fulvestrant, radium-223 and many more and we’d be thrilled to help you transform your idea into a high-level strategic clinical trial by applying our simple method:

First off, you confidentially send us your idea… a few lines, or a short synopsis is all we need.

Then, your idea will be reviewed by our network of cancer experts while our statistician develops a realistic scenario for the study to be carried out.

Lastly, we confidentially present the proposal to a potential funder, negotiating a win-win situation that satisfies all parties.

If the project is approved, you will join our team and play a lead role in all study aspects all the way through to the publication of study results. Meanwhile, our clinical operations team professionally manages the trial, respecting ISO 9001-certified quality, while placing a major focus on accrual timelines: The faster we move, the quicker we can produce results and improve patient lives.


50% Recruitment Stage 1 in DxCARTES Study

MedSIR is delighted to announce that DxCARTES study achieves a new milestone: 50% recruitment completed in stage 1. We currently have 15 patients recruited and 39 screenings have been sent to Central lab...
READ MORE...
First Patient in BARBICAN Study

We are very pleased to announce that the first two Spanish patients have been successfully randomized in the Study by Dr. Viñas and her team from Hospital Josep Trueta (ICO) last June and have started treatment...
READ MORE...
First Patient in REVERT study

Welcome to the first patient in REVERT study. This is a multicenter, randomized, phase II trial evaluating the efficacy of eribulin monotherapy and eribulin plus endocrine therapy in locally- recurrent or metastatic breast cancer patients...
READ MORE...
ASCO Annual Meeting 2019 Highlights

The 2019 Annual Meeting of the American Society of Clinical Oncology (ASCO) was characterized by a great number of presentations of novel and potentially practice-changing clinical trial data. The event was held...
READ MORE...
A great moment for MedSIR in OM3d

The IV Foro en Oncología Médica en 3 Días (OM3d) was celebrated on May 8 to 10, and MedSIR was there attending it in Madrid Teatro Goya. This is the most important congress with Spanish oncologists...
READ MORE...
First Patient In DxCARTES study

MedSIR has enrolled the first patient in DxCARTES: Neoadjuvant letrozole and palbociclib in patients with stage II-IIIB breast cancer, HR/HER2 phenotype and pre-treatment Recurrence Score® (RS)...
READ MORE...